Skip to main content
OpenTrials
Completed

NCT Number: NCT03078322

AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

The study will evaluate the safety and efficacy of AV-101.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

VistaGen Investigational Site, Garden Grove, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with MDD, single or recurrent, and currently experiencing a MDE of at least 8 weeks in duration.
  • Has a history of inadequate response to at least 1 approved antidepressant including at least 1 and no more than 3 during the current depressive episode.
  • Meet the threshold on the total HAMD-17 score of > 20
  • If female, a status of nonchildbearing potential or use of an acceptable form of birth control.
  • Body mass index between 18 to 40 kg/m2.
  • Other criteria may apply

Exclusion criteria

  • History of bipolar disorder, schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes.
  • Any Axis I or Axis II Disorder, which at screening is clinically predominant to their MDD or has been predominant to their MDD at any time within 6 months prior to screening.
  • Women who are pregnant or breastfeeding or a positive pregnancy test at screening or baseline.
  • Currently taking a prohibited adjunct therapy. Such drugs must be washed out for at least 4 weeks prior to baseline.
  • Current diagnosis of moderate or severe substance use (including alcohol) disorder (abuse or dependence, as defined by DSM-5), with the exception of nicotine dependence, at screening or within 6 months prior to screening.
  • In the opinion of the investigator, the subject has a significant risk for suicidal behavior
  • Has received electroconvulsive therapy, or had repetitive transcranial magnetic stimulation in the current episode.
  • Has received vagus nerve stimulation at any time prior to screening.
  • Any current or past history of any physical condition, which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.

Treatment and study plan

AV-101

Drug

Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)

Other names: L-4-chlorokynurenine

Placebo

Drug

Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)

Primary outcomes

  1. Montgomery Åsberg Depression Rating Scale 10-item version (MADRS-10)

    Time frame: 2 weeks

    Depression questionnaire

Secondary outcomes

  1. Time course of improvement including response rates

    Time frame: 2 weeks

    50% improvement on MADRS-10

  2. Safety and tolerability will be assessed by incidence of adverse events (AEs)

    Time frame: 2 weeks

    Also include EKG, labs etc.

Sponsors and collaborators

Lead sponsor

VistaGen Therapeutics, Inc.

Industry

Registry information

Official study title

Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (the ELEVATE Study)

Acronym: ELEVATE

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Mar 13, 2017
Registry last updated
Oct 9, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.